PPP1R3C Antibody

Introduction to PPP1R3C Antibody

PPP1R3C antibodies target the regulatory subunit of protein phosphatase 1 (PP1), which modulates glycogen synthesis and degradation. PPP1R3C binds PP1 to enhance glycogen synthase activity, promoting glycogen storage . Dysregulation of PPP1R3C is linked to metabolic disorders, including diabetes and cancer .

Antibody Characteristics

Key properties of commercially available PPP1R3C antibodies include:

Functional Insights

• Glycogen Metabolism: PPP1R3C overexpression increases hepatic gluconeogenesis, while its knockdown suppresses glycogen levels .

• Hypoxia Response: Induces glycogen accumulation via HIF1α during hypoxia, implicating it in cancer progression (e.g., melanoma) .

• Gene Expression:

  • In human muscle biopsies, PPP1R3C mRNA levels are comparable to reference genes, but drop 14-fold in cultured myotubes .

  • PPP1R3A (G_M) expression decreases dramatically (~3,400-fold) in vitro compared to muscle tissue .

Table 1: Relative mRNA Expression in Muscle vs. Cultured Myotubes

Applications in Experimental Models

• Western Blot (WB): Validated in HEK-293T cells, mouse cerebellum, and rat cerebellum .

• Immunohistochemistry (IHC): Detected in human colon cancer tissues with antigen retrieval using TE buffer (pH 9.0) .

• Knockout Models: CRISPR/Cas9-generated PPP1R3C knockout HeLa cells (1 bp deletion in exon 2) enable functional studies .

Therapeutic and Diagnostic Relevance

• Metabolic Disorders: PPP1R3C’s role in glycogen storage links it to type 2 diabetes and hepatic gluconeogenesis .

• Cancer Research: Hypermethylation of PPP1R3C in melanoma suggests potential as a biomarker or therapeutic target .

Protocol Considerations

• Optimization: Titration is required for optimal results in WB and IHC due to sample variability .

• Storage: Stable at -20°C; aliquoting is unnecessary for long-term storage .